Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS)

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. has a significant shareholder group led by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, which jointly report beneficial ownership of 1,812,031 shares of common stock. This represents 9.25% of the outstanding common stock, with the calculation based on 19,570,972 shares outstanding as of August 10, 2026.

The reporting persons state they have sole voting and sole dispositive power over all 1,812,031 shares and no shared voting or dispositive power. Streeterville Capital LLC and Streeterville Management LLC are Utah limited liability companies, and John M. Fife is a United States citizen, with their principal business office in Chicago, Illinois.

Key Figures

Shares beneficially owned: 1,812,031 shares Percent of class: 9.25% Shares outstanding: 19,570,972 shares

3 metrics

Shares beneficially owned 1,812,031 shares Common stock of Vivos Therapeutics beneficially owned by the reporting persons

Percent of class 9.25% Ownership percentage of Vivos Therapeutics common stock reported on Schedule 13G

Shares outstanding 19,570,972 shares Shares of Vivos Therapeutics common stock outstanding as of August 10, 2026; baseline for ownership

Key Terms

beneficially owned, sole dispositive power, Schedule 13G

3 terms

beneficially owned financial

"shares of common stock of the Issuer that are directly beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power financial

"Sole Dispositive Power 1,812,031.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"This report is filed by Streeterville Capital LLC... on Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 01:29 PM Accepted by SEC EDGAR 08/11/2026 - 01:28 PM Learn about SEC filing dates

FAQ

What percentage of Vivos Therapeutics (VVOS) does Streeterville Capital report owning?

Streeterville Capital and related reporting persons report owning 9.25% of Vivos Therapeutics’ common stock, representing 1,812,031 shares. This ownership percentage is calculated using 19,570,972 shares outstanding as of August 10, 2026.

How many Vivos Therapeutics (VVOS) shares are beneficially owned by the Streeterville group?

The Streeterville group reports beneficial ownership of 1,812,031 shares of Vivos Therapeutics common stock. They also report sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive authority.

Who are the reporting persons on this Schedule 13G for Vivos Therapeutics (VVOS)?

The reporting persons are Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife. The shares are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting persons, who file jointly regarding this stake.

What is the share count used to calculate the 9.25% stake in Vivos Therapeutics (VVOS)?

The reported 9.25% ownership is based on 19,570,972 shares outstanding of Vivos Therapeutics common stock as of August 10, 2026. Using this share count, the Streeterville group’s 1,812,031 shares equate to the disclosed percentage of the class.

What voting and dispositive powers does the Streeterville group report over VVOS shares?

The Streeterville group reports sole power to vote and sole power to dispose of all 1,812,031 shares of Vivos Therapeutics common stock. They report zero shared voting power and zero shared dispositive power over these securities.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Vivos Therapeutics, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

92859E207

(CUSIP Number)

08/11/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92859E207

1

Names of Reporting Persons

Streeterville Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UTAH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,812,031.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,812,031.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,812,031.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Based on 19,570,972 shares outstanding as of August 10, 2026.

SCHEDULE 13G

CUSIP Number(s): 92859E207

1

Names of Reporting Persons

Streeterville Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UTAH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,812,031.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,812,031.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,812,031.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Based on 19,570,972 shares outstanding as of August 10, 2026.

SCHEDULE 13G

CUSIP Number(s): 92859E207

1

Names of Reporting Persons

John M Fife

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,812,031.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,812,031.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,812,031.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Based on 19,570,972 shares outstanding as of August 10, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vivos Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON, COLORADO, 80120
Item 2.
(a)	Name of person filing: This report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife with respect to the shares of common stock of the Issuer that are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting and filing persons.
(b)	Address or principal business office or, if none, residence: 300 East Randolph Street, Suite 40.150 Chicago, IL 60601
(c)	Citizenship: Streeterville Capital LLC is a Utah limited liability company. Streeterville Management LLC is a Utah limited liability company. John M. Fife is a United States citizen.
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP Number(s): 92859E207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,812,031
(b)	Percent of class: 9.25%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,812,031
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,812,031
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Streeterville Capital LLC

Signature:	John Fife
Name/Title:	President
Date:	08/11/2026

Streeterville Management, LLC

Signature:	John Fife
Name/Title:	President
Date:	08/11/2026

John M Fife

Signature:	John Fife
Name/Title:	John Fife
Date:	08/11/2026